Clinical trials: Olverembatinib
Ph+ ALL, Bone Marrow Transplant
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Hematopoietic stem cell transplantation (HSCT) is the effective and even the only cure treatment option for ph+ acute lymphocyte leukemia (ph+ALL).
- Conditions
- Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease
- Trial name
- NCT05603156
- Testing
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Named Patient Program for Olverembatinib (HQP1351)
This program will allow eligible patients access to Ascentage Pharma's novel drug candidate Olverembatinib (approved in China) on a named patient basis in over 100 countries ( with the exception of the USA and China) and regions…
- Trial name
- NCT05594758
- Testing
- Olverembatinib
- Sponsor
- Ascentage Pharma Group Inc.
Philadelphia-Positive ALL
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
This is a multicenter, prospective, phase II study for adult de novo Philadelphia chromosome-positive acute lymphoid leukemia (Ph+ ALL) based on the combination of Olverembatinib and Blinatumomab.
- Trial name
- NCT05931757
- Testing
- Olverembatinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Soochow University
GIST
A Study of Olverembatinib in SDH-deficient GIST.
An international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously…
- Trial name
- NCT06640361
- Testing
- Olverembatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.
- Trial name
- NCT06401603
- Testing
- Decitabine, Listaftoclax, Olverembatinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Pharmacokinetic, Olverembatinib
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
This is a non-randomized, open-label, parallel, single-dose study to evaluate the pharmacokinetic profile of olverembatinib in participants with normal or impaired liver function.
- Trial name
- NCT07282093
- Testing
- Olverembatinib 20mg
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Myeloid Leukemia, Chronic Phase
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors.
- Trial name
- NCT04126681
- Testing
- HQP1351, Hydroxyurea or Interferon-based therapy, Homoharringtonine
- Where
- 22 sites in China
- Volunteers
- 144 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Myeloid Leukemia, Chronic Phase
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) harboring T315I mutation.
- Trial name
- NCT03883087
- Testing
- HQP1351
- Where
- 10 sites in China
- Volunteers
- 41 people
- Sponsor
- Ascentage Pharma Group Inc.